Evolus (EOLS)
(Real Time Quote from BATS)
$11.62 USD
+0.19 (1.66%)
Updated Apr 29, 2024 09:38 AM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
EOLS 11.62 +0.19(1.66%)
Will EOLS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EOLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EOLS
3 Top Stocks to Invest in for Amazing Earnings Acceleration
4 Stocks to Buy for Attractive Earnings Acceleration
EOLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?
Other News for EOLS
Evolus to Report First Quarter Financial Results on May 7, 2024
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Evolus discloses publication of Phase 2 study data of 40U Jeuveau
AbbVie working with FDA after reports of fake Botox versions
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)